usd may pm et
summari develop manufactur distribut continu glucos monitor system
nm price-to-earnings oper ep
risk assess reflect fact
produc sell one product although compani
littl debt yet gener annual net incom
compani face formid competit much
larger compani primarili
jul ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
may pm stock trade
expect dxcm sale grow
billion follow two year
believ
market continu glucos
monitor began take due
launch dxcm cgm abbott
freestyl libr cgm think cgm
technolog allow diabet much
better control blood sugar level
tradit finger stick blood sugar test
rapidli becom standard care
continu invest heavili develop
next gener devic
like launch late six month
behind schedul
disrupt incorpor verili
involv support futur demand
wildli success upcom
set third manufactur
facil malaysia
expect achiev basi
point bp gross margin expans
bp oper margin
expans due increas
although share may trade
fair valu estim base dcf model
optimist assumpt hold
rate share recent sale
perform frequent surpris
upsid addit uncertain
larg opportun hospit
set fda allow
emerg use certain
hospit set purpos
enabl remot monitor patient
think temporari author could
provid data acceler broader
approv cgm use hospit set
downsid risk target opinion
includ posit develop competitor
delay smaller-than-expect hospit
opportun upsid risk includ increas
willing third parti payer
reimburs type diabet posit updat
hospit use opportun posit
base dcf model
revenu compound-annual-growth-rate
oper margin target price
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
overview found aim address need diabet design
manufactur market continu glucos monitor cgm product potenti
enabl peopl diabet achiev sustain glycem control would help reduc
diabetes-rel health issu intern diabet feder estim million adult
year age live diabet number rise million
receiv approv first gener cgm
march receiv fda approv gener cgm call
signific enhanc predecessor elimin need finger stick
calibr confirm blood glucos level second cgm without finger stick
approv fda first freestyl libr flash approv
six month prior aim commerci introduc next gener devic late
earli incorpor verili alphabet research organ involv
object becom lead provid cgm system relat product compani
focus develop commerci product integr cgm technolog insulin deliveri
system partner dxcm partner insulin deliveri includ tandem
busi segment one oper segment compani primarili focus
design develop commerci cgm system primarili deriv revenu
fiscal unit state revenu outsid grew year-over-year
reach million fy million fy percentag total revenu revenu
outsid increas fy fy fy
competit landscap market blood glucos monitor devic highli competit
constantli chang substanti impact introduct new product enhanc
sell platinum mobil system compet directli larg conglomer
roch diagnost johnson johnson abbot laboratori panason healthcar hold
also manufactur market product single-point finger stick devic collect
compani make global sale self-monitor glucos test system regard
short-term continu intermitt flash glucos monitor devic primarili compet
inc
collabor agreement verili life scienc research organ jointli
develop seri next-gener cgm product see aggress explor extend
product portfolio categori peopl diabet includ type diabet
non-insulin use peopl pre-diabet peopl obes
merger acquisit made recent signific acquisit
trend revenu grow rapidli year end
compani five-year compound annual growth rate compound-annual-growth-rate year-over-year revenu growth
invest heavili research develop spent averag
revenu compani gener maintain net cash posit
howev achiev first year profit normal basi
senior vice-president financ
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu usd
bullish sinc april technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
next month neg
recess concern although
medic devic sub-industri
histor defens recess resist
nonetheless expect near-term result
wors recent year despit neg
outlook think medic devic compani
fare much better compani
industri health care essenti
peopl expect
neg impact global procedur volum
procedur volum could quickli return
worst diseas impact pass
continu achiev robust organ growth
 mid-to-high single-digit revenu growth
driven new product grow
emerg market exposur howev expect
revenu neg impact
basi point result
mean anticip organ growth
low-single-digit
long run gener see posit
fundament trend medic devic
demand cost-effect value-bas health
care age popul rise outlay
result steadi flow
innov product revenu growth
 medic devic regul
mdr go effect may
follow vitro devic
regul ivdr goe effect
devic compani made much commentari
around introduct mdr reason
believ new regul could
neg impact industri exampl
juli submit letter
world trade organ request
mdr ivdr delay three year also
novemb european medic devic
trade associ critic slow
piecem implement new
accord evalu
billion valu prior
five-year averag deal total
billion industri debt level measur
net debt rel total capit appear
declin substanti follow
sever year increas think
industri could see increas deal
especi new ceo sever
major firm
prior concern expect
industri earn rise low-double-digit
percentag driven sale new product
command higher margin expect
industri earn rise mid-single-digit
percentag origin project
industri oper ebit margin
estim margin
think margin
like flat year-over-year
year date march health
equip sub-index declin
vs declin
composit index health
increas valu
base index
five-year market price perform may
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
et cfra reiter hold opinion share inc
cut target base dcf model
ep vs exceed consensu estim
strong sale volum growth increas global awar benefit
real-tim continu glucos monitor lift ep
ep sale increas year-over-year
million significantli exceed expect -- led growth intern
revenu follow growth revenu lift revenu
guidanc high end previou guidanc compani lower
expect gross oper margin due stronger-than-expect
price headwind howev expect margin weak temporari
introduct new transmitt autom manufactur
enabl exit year gross margin nearli roughli basi
point anticip full-year gross margin /kevin huang cfa
et cfra keep hold opinion share inc
lift target base discount cash flow
model ep vs substanti exceed estim
higher-than-expect oper leverag rais ep
initi ep sale increas
year-over-year million sale growth
million intern sale growth million continu
anticip late earli launch next gener
continu glucos monitor cgm incorpor verili
alphabet research organ involv aim doubl
manufactur capac keep cgm demand adopt cgm
technolog continu grow rapid pace despit expect price headwind
due payer mix shift expect increas sale volum higher oper
leverag drive margin improv /kevin huang cfa
analyst research note compani news
et cfra keep hold opinion share inc
lift target price base discount
cash flow model assum revenu compound-annual-growth-rate
oper margin ep vs beat consensu
expect ad record number new patient
season weak quarter rais ep estim
ep sale increas year-over-year
million sale grew intern sale grew despit
weak toward tail end although suspend full-year
guidanc compani sound bullish near-term opportun
arisen grow use telemedicin increas appreci
real-tim connect virtual monitor capabl
latter trend result temporari fda approv use
et cfra maintain hold opinion share inc
lift target price base
discount cash flow model assum revenu compound-annual-growth-rate
oper margin ep vs
significantli exceed consensu expect expect
report better-than-anticip oper margin rais ep
start ep sale increas
year-over-year million sale grew intern
sale grew full-year revenu grew yoy -- follow growth
-- way beyond dxcm guidanc januari growth
midpoint track full-scal launch
next-gener devic support futur demand
work set third manufactur facil outsid
despit price headwind primarili due mix shift expect achiev
basi point gross margin expans /kevin huang cfa
et cfra keep hold opinion share inc
lift target price base discount
cash flow model ep vs significantli exceed consensu
expect much higher expect sale rais ep
estim ep sale
increas year-over-year million sale grew
intern sale grew result stun sale
acceler quarter anticip full year sale growth
initi expect gross margin benefit
new lower-cost transmitt design howev compani experienc
challeng one autom sensor product line late
lower gross margin expect
basi point bp hand lift oper
margin estim bp sale growth substanti outpac
et cfra reiter hold opinion share inc
lift target base discount cash
flow model ep vs surpass estim
lift ep ep
sale increas year-over-year million exceed expect led
 revenu growth intern growth dxcm
revenu growth continu driven strong new patient addit
reach record level awar real-tim continu glucos monitor
increas expect sale grow vs
prior expect re-affirmed timelin next gener
cgm work verili limit launch late
full launch compani also reconfirm expect
exit gross margin almost low rang
driven primarili lower cost transmitt overal solid
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share
grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
redistribut reproduct prohibit without prior written permiss copyright cfra
content includ rate credit-rel analys data valuat model softwar
applic output therefrom part thereof content may modifi
revers engin reproduc distribut form mean store
databas retriev system without prior written permiss cfra content shall
use unlaw unauthor purpos cfra third-parti provid
well director offic sharehold employe agent guarante
accuraci complet timeli avail content
past perform necessarili indic futur result
document may contain forward-look statement forecast forecast
reliabl indic futur perform
report intend constitut offer solicit buy sell
secur engag invest activ report inform purpos
recommend report made respect particular investor
type investor secur financi instrument strategi mention herein may
suitabl investor materi intend specif investor
take account investor particular invest object financi situat
need act recommend materi consid whether
suitabl particular circumst necessari seek profession advic
cfra may licens certain intellectu properti provid servic otherwis
busi relationship certain issuer secur subject cfra
research report includ exchange-trad invest whose invest object
substanti replic return proprietari index cfra case cfra
paid fee tie amount asset invest fund volum trade
activ fund invest fund may result cfra receiv compens
addit subscript fee compens servic render cfra
howev part cfra compens servic tie recommend
rate addit inform subject compani may avail upon request
cfra financi data provid global market intellig document contain
global industri classif standard gic develop and/or exclus
properti inc global market intellig gic servic mark
 global market intellig licens use cfra
disclaim notic
certain inform report provid global inc and/or affili
subsidiari collect global inform subject follow
disclaim notic copyright global market intellig affili
applic right reserv noth contain herein invest advic
refer particular invest secur credit rate observ
concern secur invest provid recommend buy
sell hold invest secur make invest decis may
contain inform obtain third parti includ rate credit rate
agenc reproduct distribut inform third parti content
form prohibit except prior written permiss global
relat third parti applic neither third parti provid guarante
accuraci complet timeli avail inform includ rate
respons error omiss neglig otherwis regardless
caus result obtain use inform content
includ rate credit rate statement opinion statement
fact recommend purchas hold sell secur address
suitabl secur suitabl secur invest purpos
reli invest advic
